We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Editorial

Impact of chromosomal translocation and genomic instability on personalized medicine

    Zhangguo Chen

    Integrated Department of Immunology, University of Colorado School of Medicine & National Jewish Health, Denver, CO 80206, USA

    Search for more papers by this author

    &
    Jing H Wang

    * Author for correspondence

    Integrated Department of Immunology, University of Colorado School of Medicine & National Jewish Health, Denver, CO 80206, USA.

    Search for more papers by this author

    Email the corresponding author at jing.wang@ucdenver.edu

    Published Online:27 Feb 2013https://doi.org/10.2217/pme.12.123
    Free first page

    References

    • 1  Langreth R, Waldholz M. New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist4(5),426–427 (1999).
      Medline CASGoogle Scholar
    • 2  Jorgensen JT. New era of personalized medicine: a 10-year anniversary. Oncologist14(5),557–558 (2009).
      MedlineGoogle Scholar
    • 3  Bates S. Progress towards personalized medicine. Drug Discov. Today15(3–4),115–120 (2010).
      MedlineGoogle Scholar
    • 4  Wang JH. Mechanisms and impacts of chromosomal translocations in cancers. Front. Med.6(3),263–274 (2012).
      MedlineGoogle Scholar
    • 5  Rowley JD. Chromosome translocations: dangerous liaisons revisited. Nat. Rev. Cancer1(3),245–250 (2001).
      Medline CASGoogle Scholar
    • 6  Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood105(7),2640–2653 (2005).
      Medline CASGoogle Scholar
    • 7  Huang ME, Ye YC, Chen SR et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood72(2),567–572 (1988).
      Medline CASGoogle Scholar
    • 8  Chen GQ, Shi XG, Tang W et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood89(9),3345–3353 (1997).
      Medline CASGoogle Scholar
    • 9  Shen ZX, Chen GQ, Ni JH et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood89(9),3354–3360 (1997).
      Medline CASGoogle Scholar
    • 10  Sun H, Ma L, Hu X, Zhang T. Treatment of acute promyelocytic leukemia by Ailing-1 therapy with use of syndrome differentiation of traditional Chinese medicine. Chin. J. Comb. Trad. Chin. Med. West. Med.12,170–171 (1992).
      Google Scholar
    • 11  Warrell RP Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N. Engl. J. Med.329(3),177–189 (1993).
      Medline CASGoogle Scholar
    • 12  Kakizuka A, Miller WH Jr, Umesono K et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell66(4),663–674 (1991).
      Medline CASGoogle Scholar
    • 13  Shen ZX, Shi ZZ, Fang J et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA101(15),5328–5335 (2004).
      Medline CASGoogle Scholar
    • 14  Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science331(6024),1553–1558 (2011).
      Medline CASGoogle Scholar
    • 15  Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability – an evolving hallmark of cancer. Nat. Rev. Mol. Cell. Biol.11(3),220–228 (2010).
      Medline CASGoogle Scholar
    • 16  Nowell PC. The clonal evolution of tumor cell populations. Science194(4260),23–28 (1976).
      Medline CASGoogle Scholar
    • 17  Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature458(7239),719–724 (2009).
      Medline CASGoogle Scholar
    • 18  Roschke AV, Kirsch IR. Targeting karyotypic complexity and chromosomal instability of cancer cells. Curr. Drug Targets11(10),1341–1350 (2010).
      Medline CASGoogle Scholar
    • 19  Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417(6892),949–954 (2002).
      Medline CASGoogle Scholar
    • 20  Solit D, Sawyers CL. Drug discovery: how melanomas bypass new therapy. Nature468(7326),902–903 (2010).
      Medline CASGoogle Scholar
    • 21  Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature468(7326),968–972 (2010).
      Medline CASGoogle Scholar
    • 22  Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature468(7326),973–977 (2010).
      Medline CASGoogle Scholar
    • 23  Poulikakos PI, Persaud Y, Janakiraman M et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature480(7377),387–390 (2011).
      Medline CASGoogle Scholar
    • 24  Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet.38(9),1043–1048 (2006).
      Medline CASGoogle Scholar
    • 25  Lee AJ, Endesfelder D, Rowan AJ et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res.71(5),1858–1870 (2011).
      Medline CASGoogle Scholar
    • 26  Swanton C, Nicke B, Schuett M et al. Chromosomal instability determines taxane response. Proc. Natl Acad. Sci. USA106(21),8671–8676 (2009).
      Medline CASGoogle Scholar
    • 27  Wallqvist A, Huang R, Covell DG, Roschke AV, Gelhaus KS, Kirsch IR. Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells. Mol. Cancer Ther.4(10),1559–1568 (2005).
      Medline CASGoogle Scholar
    • 28  Jain KK. Personalized medicine. Curr. Opin Mol. Ther.4(6),548–558 (2002).
      Medline CASGoogle Scholar
    • 29  Unschuld PU. Huang Di Nei Jing Su Wen: Nature, Knowledge, Imagery in an Ancient Chinese Medical Text. Appendix: the Doctrine of the Five Periods and Six Qi in the Huang Di Nei Jing Su Wen. University of California Press, Berkeley, CA, USA (2003).
      Google Scholar
    • 30  Kang YJ. Herbogenomics: from traditional Chinese medicine to novel therapeutics. Exp. Biol. Med. (Maywood)233(9),1059–1065 (2008).
      Medline CASGoogle Scholar
    • 31  Uzuner H, Bauer R, Fan TP et al. Traditional Chinese medicine research in the post-genomic era: good practice, priorities, challenges and opportunities. J. Ethnopharmacol.140(3),458–468 (2012).
      MedlineGoogle Scholar
    • 32  Zhang A, Sun H, Wang P, Han Y, Wang X. Future perspectives of personalized medicine in traditional Chinese medicine: a systems biology approach. Complement. Ther. Med.20(1–2),93–99 (2012).
      MedlineGoogle Scholar
    • 33  Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat. Med.17(3),297–303 (2011).
      Medline CASGoogle Scholar
    • 34  Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat. Rev.35(1),18–31 (2009).
      Medline CASGoogle Scholar
    • 101  President’s Council of Advisors on Science Technology. Priorities for Personalised Medicine (2008). www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf
      Google Scholar